Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
52 hedge funds and large institutions have $142M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
10% more capital invested
Capital invested by funds: $130M → $142M (+$12.6M)
8% more funds holding
Funds holding: 48 → 52 (+4)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$4.83M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$3.71M |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
+$3.68M |
| 4 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$2.45M |
| 5 |
Millennium Management
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$4.87M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.26M |
| 3 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$1.08M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$706K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$488K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| $329 | +$328K | +33,396 | New |
|
|
KC
52
Kepos Capital
New York
| – | -$4.87M | -500,000 | Closed |
|
|
BCM
53
Basso Capital Management
Stamford,
Connecticut
| – | -$488K | -50,124 | Closed |
|
|
LOAMU
54
Lombard Odier Asset Management (USA)
New York
| – | -$487K | -49,989 | Closed |
|
ORIA Hedge Fund Activity: Q3 2022 in Review
52 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q3 2022, worth a combined $142M — up 9.7% from $130M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORIA positions and 3 closed out — a net gain of 5 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $4.83M. The largest seller was Kepos Capital, exiting entirely with an estimated $4.87M sold.
- 52 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q3 2022, up from 48 in Q2 2022.
- Funds reported $142M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q3 2022, up 9.7% quarter-over-quarter.
- 8 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q3 2022 and 3 closed out, a net change of +5 holders.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q3 2022 was Magnetar Financial, an estimated $4.83M added.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q3 2022 was Kepos Capital, an estimated $4.87M sold.
Based on aggregated 13F filings for Q3 2022.